Jun 2026 (Q2 FY26) — Aug 14, 2026
Vivos Therapeutics Q2 FY26 — Strategic Pivot Drives Revenue Growth Amidst Going Concern Warning
Read the full callVivos Therapeutics (VVOS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Vivos Therapeutics earnings: last reported Fri, 14 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 5.2 | +34.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -93.6 | +33.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -5.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.13 0.00% · $0
Performance −95.5% 1Y
1Y: $2.9 on 17 Oct 2025 → $0.13. High $3.01 (24 Oct 2025), low $0.13 (28 Sept 2026).
- Previous close
- $0.13
- 52-week range
- $0.13 – $3.01
- One year
- −95.44%
Overview
- Symbol
- VVOS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Vivos Therapeutics earnings calls (VVOS)
Financials
What the filings say
Net profit, year on year: −9% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 4 | 3 | 4 | 7 | 4 | 5 | 5 |
| Operating profit | -3 | -3 | -4 | -5 | -5 | -6 | -7 | -5 |
| Operating margin | −68.5% | −75.8% | −129.9% | −127.4% | −69.8% | −166.8% | −128.7% | −93.6% |
| Interest | — | — | — | — | 1 | 1 | 1 | 1 |
| Profit before tax | -3 | -3 | -4 | -5 | -5 | -7 | -8 | -6 |
| Net profit | -3 | -3 | -4 | -5 | -5 | -7 | -8 | -5 |
| EPS ($ per share) | -0.40 | — | -0.45 | -0.55 | -0.49 | — | -0.52 | -0.31 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | — | — | 0 |
| Reserves | -23 | -35 | -56 | -79 | -93 | -104 | -125 |
| Total liabilities | 9 | 8 | 8 | 9 | 10 | 7 | 27 |
| Fixed assets | 1 | 1 | 3 | 3 | 3 | 3 | 4 |
| Total assets | 8 | 25 | 34 | 14 | 11 | 15 | 25 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -5 | -6 | -16 | -20 | -12 | -13 | -15 |
| Cash from investing | 0 | -0 | -3 | -1 | -1 | -1 | -8 |
| Cash from financing | 4 | 24 | 24 | — | 11 | 18 | 19 |
| Net cash flow | -1 | 18 | 6 | -21 | -2 | 5 | -4 |
| Capital expenditure | -0 | -0 | -2 | -1 | -1 | -1 | -2 |
| Free cash flow | -6 | -6 | -18 | -21 | -13 | -13 | -18 |
Insider filings
4 filings between Mar 31, 2026 and Jul 31, 2026.
Open market
decisions to buy or sellPurchases
$1.81M
2 purchases by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 1
- Award — granted as compensation
Also filed: 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Skaff Michael C | $1.81M | — | Mar 31, 2026 |
Latest filings (4)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 31, 2026 | Amman Bradford K. Principal Accounting Officer | Award | 250,000 | $102.5K |
| Jun 30, 2026 | Huntsman Ronald Kirk Chief Executive Officer | Other | 85,910 | $50.0K |
| Mar 31, 2026 | Skaff Michael C 10% owner | Purchase | 1,044,777 | $1.40M |
| Mar 31, 2026 | Skaff Michael C 10% owner | Purchase | 308,848 | $413.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Vivos Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Vivos Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading